Evidence map›Paper›PMID 38332436›Full record

ArticleDermatology and therapy2024

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).

Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H Chih-Ho Hong, Meghan Feely, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03573323 (A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03573323 phase4completednot on this map

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

TypeinterventionalSponsorEli Lilly and CompanyRan2018 to 2020Enrolled1,027ConditionsPlaque PsoriasisArmsIxekizumab, Guselkumab, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Melinda GooderhamQueen's University, Kingston, ON, Canada. mjgooderham@gmail.com.ORCID http://orcid.org/0000-0001-8926-0113
Ronald VenderDermatrials Research Inc., Hamilton, ON, Canada.
Jeffrey CrowleyBakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA.
H Chih-Ho HongDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Meghan FeelyEli Lilly and Company, Indianapolis, IN, USA.
Alyssa GarreltsEli Lilly and Company, Indianapolis, IN, USA.
Kyoungah SeeEli Lilly and Company, Indianapolis, IN, USA.
Bruce KonicekEli Lilly and Company, Indianapolis, IN, USA.
Lawrence GreenGeorge Washington University School of Medicine, Washington, DC, USA.
Eli Lilly (United States) · USDermatrials Research · CAGeorge Washington University · USQueen's University · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhen assessing the effect of a therapy for psoriasis (PsO), it is important to consider speed of response and cumulative response. However, responses among biologics may differ by body regions. This post hoc analysis compares speed of response and cumulative response for ixekizumab (IXE), an interleukin-17A antagonist, and guselkumab (GUS), an interleukin-23p19 inhibitor, in different body regions of patients with moderate-to-severe plaque PsO participating in the IXORA-R study, up to week 24.

methodsThe IXORA-R design has been previously described. Patients received the respective on-label dosing of IXE or GUS. The median time to first Psoriasis Area and Severity Index (PASI) 50, 75, 90, and 100 response (50%, 75%, 90%, and 100% improvement from baseline, respectively) and the cumulative days with clear skin for PASI 50, 75, 90, and 100 responses were assessed in four body regions: head, trunk, upper extremities, and lower extremities.

resultsA total of 1027 patients were enrolled and received IXE (N = 520) or GUS (N = 507). Median time to first PASI 50, 75, 90, and 100 response was shortest in the head region, followed by the remaining body regions in both IXE and GUS cohorts. In each body region, IXE was significantly faster than GUS (p < 0.001) in achieving PASI 50, 75, 90, and 100. Through 24 weeks, the number of days with clear skin for PASI 90 and 100 was greater in the head region, followed by trunk, upper extremities, and lastly lower extremities in both IXE and GUS cohorts. In each body region, through 24 weeks, patients on IXE experienced a significantly higher number of days with clear skin for PASI 50, 75, 90, and 100 than patients on GUS (p < 0.01).

conclusionsAs compared to GUS, IXE provided a faster skin clearance and more days with clear skin in all body regions of patients with moderate-to-severe plaque PsO through 24 weeks. TRIAL REGISTRATION NUMBER: https://www. CLINICALTRIALS: gov/ : NCT03573323 (IXORA-R).

Indexed as

Body regionsCumulative responseIxekizumabIXORA-RModerate-to-severe plaque psoriasisPASISpeed of response

Identifiers

PMID38332436
PMCPMC10890986
OpenAlexW4391689991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.